In addition, although individuals receiving sulfonylurea therapy are likely to have type 2 diabetes, those who receive insulin only may include individuals with type 1 diabetes for whom insulin deintensification or discontinuation may be inappropriate. The gene discussed is INS; the disease is type 2 diabetes mellitus.